Objective: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), primarily targets the respiratory system. This study describes the characteristics associated with mortality among patients infected with SARS-CoV-2 at a single hospital in Baguio City, Philippines. Methods: We reviewed medical records (including history, laboratory results and treatment regimen) of 280 confirmed COVID-19 patients admitted to a single hospital during March–October 2020. Clinical characteristics and outcomes (frequency and type of complication, recovery rate and mortality) were evaluated. Multiple logistic regression was used to analyse factors associated with mortality. Results: The mean age of COVID-19 patients was 48.4 years and the female-to-male ratio was 1.8:1. Hypertension, cardiovascular disease (CVD) and diabetes were the most frequent comorbidities reported. Common presenting symptoms were respiratory and constitutional, with 41% of patients not reporting symptoms on admission. Patients with moderate, severe and critical disease comprised 45%, 8% and 4%, respectively. A total of 15% had complications, health care-associated pneumonia being the most frequent complication. The recovery rate was 95%; 5% of patients died, with multiorgan failure being the most common cause. The presence of CVD, chronic kidney disease, prolonged prothrombin time and elevated lactate dehydrogenase (LDH) were associated with mortality. Discussion Most COVID-19 patients in our population had asymptomatic to moderate disease on admission. Mortality from COVID-19 was associated with having CVD, chronic kidney disease, elevated LDH and prolonged prothrombin time. Based on these results, we emphasize that people should take all necessary precautions to avoid infection with SARS-CoV-2.

OBJECTIVE: The primary objective of this study was to evaluate the effectiveness of valsartan 160 mg as a starting dose for hypertension based on the percentage of responders, in terms of reduction of diastolic blood pressure (DBP), after 4 weeks treatment.The secondary objectives are to evaluate the percentage of responders - in terms of systolic blood pressure (SBP) - after 4 weeks treatment, the reduction til MsSBP and MsDBP with valsartan 1 60 mg treatment at 4 weeks, control rates (% of patients) with SBP < 140 tnmHg and DBP 160 mmHg or DBP >100 mmHg)including those patients with isolated systolic hypertension (SBP 140 mmHg/DBP
Human ; Aged ; Middle Aged ; Adult ; Young Adult ; Adolescent ; Hypertension